Literature DB >> 12190834

Menopause, energy expenditure, and body composition.

Eric T Poehlman1.   

Abstract

OBJECTIVES: The effects of menopause transition on metabolic and cardiovascular disease risk in women are unclear. It is unknown whether estrogen deficiency, aging, or a combination of both factors are independent contributors to a worsening health profile in women. We considered the effects of menopause transition and hormone replacement therapy on body composition, regional body fat, energy expenditure, and insulin sensitivity.
METHODS: A brief review of current literature that has considered the role of menopause transition and hormone replacement therapy on body composition, energy expenditure, and insulin sensitivity with an emphasis on longitudinal investigations.
RESULTS: Preliminary evidence suggests that natural menopause is associated with reduced energy expenditure during rest and physical activity, an accelerated loss of fat-free mass, and increased central adiposity and fasting insulin levels. Hormone replacement therapy has been shown to attenuate these changes. Longitudinal and longer intervention studies are needed to confirm these initial findings.
CONCLUSIONS: Menopause transition may represent a risky period in a woman's life, 'triggering' adverse metabolic and cardiovascular processes that predispose women to a greater incidence of obesity-related comorbidities. Dietary, exercise, and hormonal interventions specifically targeted at premenopausal women may help mitigate the worsening cardiovascular and metabolic risk profile associated with menopause.

Entities:  

Mesh:

Year:  2002        PMID: 12190834     DOI: 10.1034/j.1600-0412.2002.810705.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  26 in total

1.  Study on relation of metabolic syndrome with menopause.

Authors:  Sapna Goyal; Mriganka Baruah; Runi Devi; Kalpana Jain
Journal:  Indian J Clin Biochem       Date:  2012-08-03

2.  Plasma orexin A levels in recently menopausal women during and 3 years following use of hormone therapy.

Authors:  Dahima Cintron; John P Beckman; Kent R Bailey; Brian D Lahr; Muthuvel Jayachandran; Virginia M Miller
Journal:  Maturitas       Date:  2017-02-17       Impact factor: 4.342

3.  The Mediation of Hepatic Lipogenesis Through Estrogens.

Authors:  Colette N Miller; Mary Anne Della-Fera; Clifton A Baile
Journal:  Postdoc J       Date:  2013-05

Review 4.  Cross-talk between reproduction and energy homeostasis: central impact of estrogens, leptin and kisspeptin signaling.

Authors:  Casey C Nestor; Martin J Kelly; Oline K Rønnekleiv
Journal:  Horm Mol Biol Clin Investig       Date:  2014-03

Review 5.  Oestrogen modulates hypothalamic control of energy homeostasis through multiple mechanisms.

Authors:  T A Roepke
Journal:  J Neuroendocrinol       Date:  2008-12-06       Impact factor: 3.627

6.  Effect of ovariectomy on serum adiponectin levels and visceral fat in rats.

Authors:  Ce Camara; Lin-Yuan Zhou; Yan Ma; Lin Zhu; Dong Yu; Yao-Wu Zhao; Nian-Hong Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

Review 7.  Cross-talk between membrane-initiated and nuclear-initiated oestrogen signalling in the hypothalamus.

Authors:  T A Roepke; J Qiu; M A Bosch; O K Rønnekleiv; M J Kelly
Journal:  J Neuroendocrinol       Date:  2009-03       Impact factor: 3.627

8.  Metabolic syndrome in menopausal transition: Isfahan Healthy Heart Program, a population based study.

Authors:  Ramin Heidari; Masoumeh Sadeghi; Mohammad Talaei; Katayoun Rabiei; Noushin Mohammadifard; Nizal Sarrafzadegan
Journal:  Diabetol Metab Syndr       Date:  2010-10-05       Impact factor: 3.320

Review 9.  Membrane-initiated estrogen signaling in hypothalamic neurons.

Authors:  Martin J Kelly; Oline K Rønnekleiv
Journal:  Mol Cell Endocrinol       Date:  2008-04-30       Impact factor: 4.102

Review 10.  Control of CNS neuronal excitability by estrogens via membrane-initiated signaling.

Authors:  Martin J Kelly; Oline K Rønnekleiv
Journal:  Mol Cell Endocrinol       Date:  2009-03-25       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.